Zhijian Yu

424 total citations
23 papers, 306 citations indexed

About

Zhijian Yu is a scholar working on Hepatology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Zhijian Yu has authored 23 papers receiving a total of 306 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Hepatology, 7 papers in Pulmonary and Respiratory Medicine and 4 papers in Surgery. Recurrent topics in Zhijian Yu's work include Hepatocellular Carcinoma Treatment and Prognosis (8 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Cancer, Lipids, and Metabolism (3 papers). Zhijian Yu is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (8 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Cancer, Lipids, and Metabolism (3 papers). Zhijian Yu collaborates with scholars based in China and Canada. Zhijian Yu's co-authors include Gang Deng, Libin Ma, Yuyong Wang, Xianyue Quan, Ming Tang, Qi Meng, Zhiying Zhu, Yong Chen, Guangdi Chen and Lingyan Zheng and has published in prestigious journals such as International Journal of Cancer, Aging Cell and Journal of Cellular and Molecular Medicine.

In The Last Decade

Zhijian Yu

22 papers receiving 299 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zhijian Yu China 11 96 67 65 55 55 23 306
Lizhi Lv China 13 235 2.4× 81 1.2× 80 1.2× 150 2.7× 75 1.4× 42 487
A. Schuster Germany 7 133 1.4× 37 0.6× 115 1.8× 19 0.3× 57 1.0× 9 375
Manali Dimri United States 6 227 2.4× 54 0.8× 69 1.1× 107 1.9× 54 1.0× 10 401
Xiaolin Liu China 10 129 1.3× 89 1.3× 50 0.8× 106 1.9× 46 0.8× 26 329
Xiaoxun Zhang China 11 132 1.4× 82 1.2× 49 0.8× 29 0.5× 19 0.3× 21 298
Zhiming Huang China 9 140 1.5× 56 0.8× 23 0.4× 52 0.9× 26 0.5× 13 349
Marilena Castelli Italy 14 229 2.4× 43 0.6× 30 0.5× 88 1.6× 32 0.6× 23 413
Zi-Teng Zhang China 11 226 2.4× 39 0.6× 16 0.2× 66 1.2× 41 0.7× 13 369
Naomi F. Lange Switzerland 9 87 0.9× 206 3.1× 116 1.8× 35 0.6× 13 0.2× 20 321
Stamatis Theocharis Greece 10 163 1.7× 57 0.9× 14 0.2× 55 1.0× 19 0.3× 12 378

Countries citing papers authored by Zhijian Yu

Since Specialization
Citations

This map shows the geographic impact of Zhijian Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhijian Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhijian Yu more than expected).

Fields of papers citing papers by Zhijian Yu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhijian Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhijian Yu. The network helps show where Zhijian Yu may publish in the future.

Co-authorship network of co-authors of Zhijian Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Zhijian Yu. A scholar is included among the top collaborators of Zhijian Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhijian Yu. Zhijian Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
2.
Li, Weifen, Tahir Ali, Kaiwu He, et al.. (2024). ApoE4 dysregulation incites depressive symptoms and mitochondrial impairments in mice. Journal of Cellular and Molecular Medicine. 28(7). e18160–e18160. 5 indexed citations
3.
Zhao, Tingting & Zhijian Yu. (2024). Modified Gexia-Zhuyu Tang inhibits gastric cancer progression by restoring gut microbiota and regulating pyroptosis. Cancer Cell International. 24(1). 21–21. 7 indexed citations
4.
He, Kaiwu, Lulin Nie, Tahir Ali, et al.. (2021). Adiponectin alleviated Alzheimer‐like pathologies via autophagy‐lysosomal activation. Aging Cell. 20(12). e13514–e13514. 42 indexed citations
5.
Ma, Libin, et al.. (2017). Emodin inhibits the proliferation and invasion of bladder cancer cells via down-regulating Notch1.. PubMed. 10(9). 9452–9459. 11 indexed citations
6.
He, Huadong, et al.. (2016). Renal and retroperitoneal metastasis from prostate adenocarcinoma: a case report. World Journal of Surgical Oncology. 14(1). 74–74. 10 indexed citations
7.
Ge, Hongwei, Xiaoqing Zheng, Yan-qun Na, et al.. (2016). Bilateral Same-Session Ureteroscopy for Treatment of Ureteral Calculi: A Systematic Review and Meta-Analysis. Journal of Endourology. 30(11). 1169–1179. 14 indexed citations
8.
Deng, Gang, et al.. (2015). Emodin inhibits the proliferation of PC3 prostate cancer cells in vitro via the Notch signaling pathway. Molecular Medicine Reports. 12(3). 4427–4433. 29 indexed citations
9.
10.
Deng, Gang, et al.. (2015). Notch signaling in the prostate: critical roles during development and in the hallmarks of prostate cancer biology. Journal of Cancer Research and Clinical Oncology. 142(3). 531–547. 23 indexed citations
11.
Wang, Yuyong, et al.. (2014). Vitamin C and E intake and risk of bladder cancer: a meta-analysis of observational studies.. PubMed. 7(11). 4154–64. 18 indexed citations
12.
Wang, Gang, Lingyan Zheng, Zhijian Yu, et al.. (2012). Increased cyclin-dependent kinase 6 expression in bladder cancer. Oncology Letters. 4(1). 43–46. 37 indexed citations
13.
Yu, Zhijian, et al.. (2012). [Targeted injection of ozone through the posterior approach via the spinal canal and dural sac for treating lumbar disc herniation].. PubMed. 32(2). 243–6. 2 indexed citations
14.
Luo, Xinyu, et al.. (2008). Present Status and Prospect of Fluorescent Dye Used for CCFL. 32(2). 245–251. 4 indexed citations
15.
Lü, Wei, Yanhao Li, Zhijian Yu, et al.. (2007). A comparative study of damage to liver function after TACE with use of low-dose versus conventional-dose of anticancer drugs in hepatocellular carcinoma.. PubMed. 54(77). 1499–502. 32 indexed citations
16.
Yu, Zhijian, Jiawei Yu, Wei Cai, et al.. (2005). Evaluation of HCPTd1,d14-double passaged intervening chemotherapy protocol for hepatocellular carcinoma.. Europe PMC (PubMed Central). 11(33). 5221–5. 4 indexed citations
17.
Quan, Xianyue, et al.. (2005). Evaluation of diffusion weighted imaging of magnetic resonance imaging in small focal hepatic lesions: a quantitative study in 56 cases.. PubMed. 4(3). 406–9. 23 indexed citations
18.
Yu, Zhijian, et al.. (2004). [Effects of functional inhibition of p-glycoprotein on radiosensitivity of drug-resistant MCF-7/Adr tumor cells].. PubMed. 24(8). 885–7. 1 indexed citations
19.
Wu, Jianxin, et al.. (2002). [Factors related to acute upper gastrointestinal bleeding after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma].. PubMed. 21(8). 881–4. 3 indexed citations
20.
Yu, Zhijian, et al.. (2002). Combined transcatheter arterial chemoembolization and beta-ultrasound guided portal vein embolization in the treatment of hepatocellular carcinoma.. PubMed. 24(4). 391–3. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026